top of page

Inflection Biosciences Announces Pre-clinical data for IBL-101 to be Presented at BSI Congress 2022

Dublin, Ireland, December 5, 2022 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, autoimmune and inflammatory diseases today announced that new data on IBL-101, a pan-PIM kinase inhibitor, which is being developed for autoimmune and inflammatory disease, will be highlighted in a poster presentation at the British Society for Immunology Congress 2022 taking place from December 5-8, 2022 in Liverpool, U.K.

The pre-clinical data was generated through a collaboration between Inflection Biosciences and Trinity College Dublin, led by Professor Patrick T. Walsh, Department of Clinical Medicine, School of Medicine, Trinity College Dublin (TCD). National Children's Research Centre (NCRC), Children's Health Ireland Crumlin, Dublin. The collaboration was funded by Enterprise Ireland.

Professor Pat Walsh commented “The data shows that PIM genes are up-regulated in psoriatic patients’ skin and in a mouse model of psoriasis. IBL-101 was able to suppress inflammatory cytokine production and skew T helper cells towards an iTreg cell phenotype. The results provide proof of concept for IBL-101 as a potential treatment for psoriasis and other autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and lupus nephritis.”

The details for the poster presentation are as follows:

Poster Title: Investigation of a novel pan-PIM kinase inhibitor, IBL-101, as a potential treatment for psoriasis

Poster Session: 1

Time & Date: 6.00 pm – 7.30 pm; Tuesday 6, December 2022

Presenter: Dr. Yasmina Esther Hernández-Santana

Poster Board No.: 461

Location: ACC Liverpool, Hall 2

The full abstract can be viewed here.

About IBL-101

IBL-101 is a small molecule, orally available, pan-PIM kinase inhibitor in preclinical stage of development. The PIM family of serine/threonine kinases, consisting of PIM-1, PIM-2, and PIM-3, controls cell survival, proliferation, and apoptosis. PIM kinases are involved in key autoimmune and inflammatory processes through regulation of T and B cell function. Expression of PIM kinases is regulated by the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway, a critical signal transduction pathway which is dysregulated in autoimmune and inflammatory disease. JAK kinase inhibitors have been successfully developed for indications such as rheumatoid arthritis, inflammatory bowel disease and psoriasis, but carry warnings due to potential severe side effects. Downstream cellular targeting of the JAK/STAT pathway via PIM kinase inhibition may reduce the risk of these side effects thus allowing for a safer therapeutic approach.

About Inflection Biosciences

Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. IBL-101 is a pan-PIM kinase inhibitor in preclinical development for the treatment of autoimmune and inflammatory diseases. IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for aggressive B-cell malignancies, T-cell lymphoma and acute myeloid leukemia. The partnered pipeline comprises first-in-class AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. For more information, please visit

For further information contact:

Inflection Biosciences Ltd

Darren Cunningham, Chief Executive Officer


T: +353 (0)1 4003615


bottom of page